Metraipolis › archive › dc_a5a969d044ed
A humanized nanobody phage display library yields potent binders of SARS CoV-2 spike — Europe PMC PMID:35947606
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/35947606
- DOI
- 10.1371/journal.pone.0272364
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-17T05:44:07.431Z
- SHA-256 of the archived text
fafa4d735da13854a6b2978f3ead2f68d39e9d626a55f4a2ce633822712f8888- Stable URL of this page
https://metraipolis.com/documento/dc_a5a969d044ed
How to cite
A humanized nanobody phage display library yields potent binders of SARS CoV-2 spike — Europe PMC PMID:35947606 — Europe PMC (en), https://europepmc.org/article/MED/35947606 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_a5a969d044ed (Metraipolis archive dc_a5a969d044ed, sha256 fafa4d735da13854a6b2978f3ead2f68d39e9d626a55f4a2ce633822712f8888)
BibTeX
@misc{dca5a969d044ed,
title = {A humanized nanobody phage display library yields potent binders of SARS CoV-2 spike — Europe PMC PMID:35947606},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/35947606},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_a5a969d044ed; sha256 fafa4d735da13854a6b2978f3ead2f68d39e9d626a55f4a2ce633822712f8888},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/35947606. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Neutralizing antibodies targeting the SARS-CoV-2 spike protein have shown a great preventative/therapeutic potential. Here, we report a rapid and efficient strategy for the development and design of SARS-CoV-2 neutralizing humanized nanobody constructs with sub-nanomolar affinities and nanomolar potencies. CryoEM-based structural analysis of the nanobodies in complex with spike revealed two distinct binding modes. The most potent nanobody, RBD-1-2G(NCATS-BL8125), tolerates the N501Y RBD mutation and remains capable of neutralizing the B.1.1.7 (Alpha) variant. Molecular dynamics simulations provide a structural basis for understanding the neutralization process of nanobodies exclusively focused on the spike-ACE2 interface with and without the N501Y mutation on RBD. A primary human airway air-lung interface (ALI) ex vivo model showed that RBD-1-2G-Fc antibody treatment was effective at reducing viral burden following WA1 and B.1.1.7 SARS-CoV-2 infections. Therefore, this presented strategy will serve as a tool to mitigate the threat of emerging SARS-CoV-2 variants. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PloS one, 2022 (prima pubblicazione 2022-08-10). Identificativi: PMID 35947606 · PMCID PMC9365158 · DOI 10.1371/journal.pone.0272364. Descrittori MeSH principali: Bacteriophages; Single-Domain Antibodies; COVID-19. Pagina: https://europepmc.org/article/MED/35947606 — https://doi.org/10.1371/journal.pone.0272364. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-17T05:13:41.318Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.